Xu Lily, Krishnaswamy Saroja
School of Psychiatry, UNSW Medicine, Sydney, NSW, and; Department of Mental Health, Liverpool Hospital, Liverpool, NSW, Australia.
Senior Consultant Psychiatrist, Monash Health, Clayron, VIC, and; Conjoint Professor, School of Medicine, Western Sydney University, Campbelltown, NSW, and; Associate Conjoint Professor, School of Psychiatry, UNSW Medicine, Sydney, NSW, Australia.
Australas Psychiatry. 2018 Dec;26(6):635-639. doi: 10.1177/1039856218810166. Epub 2018 Nov 8.
: Switching between different antipsychotic therapies is a frequent occurrence in the management of patients with schizophrenia and other psychotic disorders. This paper provides a review of the principles of antipsychotic switching and discusses pharmacological principles underlying adverse events that occur while switching olanzapine to another antipsychotic medication. It offers suggestions for management of switch-associated adverse events in clinical settings.
: Few publications explore olanzapine switch-related adverse events, the underlying pharmacological principles and appropriate switching strategies to minimise the risk of adverse events. There is still a need for further studies to verify existing knowledge and assist in the development of 'gold standard' guidelines that outline appropriate switching strategies and duration of the switching process to reduce and avoid adverse events.
在精神分裂症和其他精神障碍患者的治疗中，频繁出现从一种抗精神病药物治疗转换至另一种的情况。本文综述了抗精神病药物转换的原则，并讨论了在将奥氮平换为另一种抗精神病药物时发生不良事件的潜在药理学原理。本文还针对临床环境中与转换相关的不良事件管理提供了建议。
很少有出版物探讨与奥氮平转换相关的不良事件、潜在药理学原理以及将不良事件风险降至最低的适当转换策略。仍需要进一步研究来验证现有知识，并协助制定“金标准”指南，该指南应概述适当的转换策略以及转换过程的持续时间，以减少和避免不良事件。
